Communiqué de presse : Le Nexviazyme de Sanofi a atteint tous les critères d’évaluation principaux et secondaires dans une étude de phase III sur la forme infantile de la maladie de Pompe

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The positive Baby-COMET results offer the potential to expand access to Nexviazyme for more patients and families facing a disease with limited therapeutic options during the earliest months of life; results are consistent with prior studies and reflect years of scientific research translating deep biological understanding into clinical advances for the Pompe disease community.

  60% confidence

• Infantile-onset Pompe disease is a devastating and rapidly progressive condition presenting in the first days or weeks of life, making early intervention essential to improve survival free of invasive ventilation beyond one year; Baby-COMET shows the potential of avalglucosidase alfa to support ventilation-free survival in infants while achieving encouraging cardiac and motor outcomes.

  60% confidence